TREATMENT DEFERRAL DURING COVID-19 LOCKDOWN: Functional and Anatomical Impact on Patients With Neovascular Age-Related Macular Degeneration.
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
pubmed:
16
12
2021
medline:
5
4
2022
entrez:
15
12
2021
Statut:
ppublish
Résumé
To investigate the visual and anatomical impact of intravitreal injection treatment deferral because of the COVID-19 lockdown on patients affected by neovascular age-related macular degeneration. We retrospectively reviewed 314 patients (394 eyes) who were scheduled to receive the impact of intravitreal injections during the Swiss lockdown. We compared patients who continued to receive scheduled impact of intravitreal treatment without clinical consultation (Group Continue ‟C"; n = 215) and patients for whom the impact of intravitreal treatment was completely deferred (Group Stop, ‟S"; n = 179). Functional and anatomical parameters were collected at four time points before and after the lockdown. In Group C, the visual acuity at baseline and after the lockdown did not differ significantly. In Group S, the visual acuity deteriorated significantly compared with baseline and then improved slightly after the resumption of treatment, but it did not recover to baseline values. The mean central subfield thickness remained stable in Group C, whereas it increased in Group S and then returned to prelockdown values after the resumption of treatment. An "injection-only" approach was effective in managing patients with neovascular age-related macular degeneration during the pandemic lockdown, whereas patients who deferred their scheduled treatment showed partially irreversible deterioration of visual function. We recommend treatment continuation in patients with neovascular age-related macular degeneration during a lockdown.
Identifiants
pubmed: 34907122
doi: 10.1097/IAE.0000000000003369
pii: 00006982-202204000-00005
pmc: PMC8946588
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
634-642Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc.
Références
Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health 2017;5:e1221–e1234.
Li JQ, Welchowski T, Schmid M, et al. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol 2020;104:1077–1084.
Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014;8:CD005139.
Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology 2021;128:234–247.
Lanzetta P, Loewenstein A, Committee VAS. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol 2017;255:1259–1273.
Mantel I, Niderprim SA, Gianniou C, et al. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. Br J Ophthalmol 2014;98:1192–1196.
Gianniou C, Dirani A, Ferrini W, et al. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye (Lond) 2015;29:450–451.
Parvin P, Zola M, Dirani A, et al. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. Graefes Arch Clin Exp Ophthalmol 2017;255:2127–2134.
Mantel I. Optimizing the anti-VEGF treatment strategy for neovascular age-related macular degeneration: from clinical trials to real-life requirements. Transl Vis Sci Technol 2015;4:6.
Swiss Federal Council. Ordinance on measures to combat the coronavirus (COVID-19). Available at: https://www.fedlex.admin.ch/eli/cc/2020/141/en .
Trivizki O, Karp MR, Chawla A, et al. Eliminating visual acuity and dilated fundus examinations improves cost efficiency of performing optical coherence tomogrpahy–guided intravitreal injections. Am J Ophthalmol 2020;219:222–230.
Laurent K. Quelle conduite à tenir adopter vis à vis des injections intravitréennes (IVT)dans cette période d'épidémie au Covid-19 - SARS-CoV-2. J Fr Ophtalmol. 2020; 43: 539–540.
Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014;98:1144–1167.
Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 2020;127:616–636.
Parke DW II. Ophthalmology after coronavirus disease 2019 (COVID-19): transition back to patient care. JAMA Ophthalmol 2020;138:599–600.
Hoeferlin C, Hosseini H. Review of clinical and operative recommendations for ophthalmology practices during the COVID-19 pandemic. SN Compr Clin Med 2021:1–6.
Safadi K, Kruger JM, Chowers I, et al. Ophthalmology practice during the COVID-19 pandemic. BMJ Open Ophthalmol 2020;5:e000487.
Framme C, Eter N, Hamacher T, et al. Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany: twelve-month outcomes of PERSEUS. Ophthalmol Retina 2018;2:539–549.
Korobelnik JF, Loewenstein A, Eldem B, et al. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol 2020;258:1149–1156.
Viola F, Milella P, Giuffrida FP, et al. The impact of coronavirus disease (COVID-19) pandemic on intravitreal injections treatment for macular diseases: report from a referral hospital in Milan. Retina 2021;41:701–705.
Romano F, Monteduro D, Airaldi M, et al. Increased number of submacular hemorrhages as a consequence of coronavirus disease 2019 lockdown. Ophthalmol Retina 2020;4:1209–1210.
Xu D, Starr MR, Boucher N, et al. Real-world vitreoretinal practice patterns during the 2020 COVID-19 pandemic: a nationwide, aggregated health record analysis. Curr Opin Ophthalmol 2020;31:427–434.
Yang KB, Feng H, Zhang H. Effects of the COVID-19 pandemic on anti-vascular endothelial growth factor treatment in China. Front Med 2020;7:1–5.
Ashkenazy N, Goduni L, Smiddy WE. Short-term effects of COVID-19-related deferral of intravitreal injection visits. Clin Ophthalmol 2021;15:413–417.
Mehta H, Tufail A, Daien V, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res 2018;65:127–146.
Soares RR, Mellen P, Garrigan H, et al. Outcomes of eyes lost to follow-up with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor. Ophthalmol Retina 2020;4:134–140.
Yeter DY, Dursun D, Bozali E, et al. Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment. J Fr Ophtalmol 2021;44:299–306.
Chakravarthy U, Pillai N, Syntosi A, et al. Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration. Eye (Lond) 2020;34:2249–2256.
Mantel I, Deli A, Iglesias K, Ambresin A. Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2013;251:697–704.